Pharmaceuticals - Community Register


Community list of not active orphan medicinal products


Product information


EU orphan designation number: EU/3/05/293
Active ingredient: nelarabine
Indication: Treatment of acute lymphoblastic leukaemia
Sponsor: Novartis Europharm Limited
Frimley Business Park, Camberley GU16 7SR, United Kingdom
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Atriance on 22/08/2007 with the number EU/1/07/403

   Public summary of scientific opinion     EPAR

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
20/06/2005 Orphan designation EMEA/OD/013/05 (2005)1881 of 16/06/2005
23/08/2006 Transfer of orphan designation EMEA/OD/013/05/T/01 (2006)3838 of 21/08/2006
04/02/2014 Change of name and/or address of sponsor
28/04/2015 Transfer of orphan designation EMA/OD/015/05/T/02 (2015)2951 of 24/04/2015
24/08/2017 Removal of orphan designation from Community Register